Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Fluticasone is a corticosteroid medication delivered as a nasal spray. It works by binding strongly to receptors in the body that respond to corticosteroids, producing a powerful anti-inflammatory effect in the airways. When sprayed into the nose, it reduces inflammation locally. The medication is approved for treating seasonal allergic rhinitis (hay fever) and year-round allergic rhinitis in adults and children aged two years and older.
After the body absorbs fluticasone, the liver breaks it down quickly using an enzyme called CYP3A4, turning it into an inactive form that the body can eliminate. The medication clears from the bloodstream quite rapidly, and the elimination process takes around ten to fifteen hours on average.
Common side effects include nosebleeds, nasal and throat inflammation, ulceration inside the nose, headache, and back pain. More serious but less common effects include allergic reactions—which can range from rash and hives to severe swelling or anaphylaxis—as well as perforation of the nasal septum (a hole forming in the wall between the nostrils). In children, there is a risk of slowed growth. Your family member should not use fluticasone if they have previously had an allergic reaction to any ingredient in the preparation.
Because fluticasone is processed by the CYP3A4 enzyme, other medications that affect this enzyme may alter how fluticasone is cleared from the body, though the nasal spray formulation delivers the medication locally and results in relatively low levels reaching the bloodstream compared to oral or injected corticosteroids.
“Fluticasone furoate is a synthetic trifluorinated corticosteroid that possesses a very high affinity for the glucocorticoid receptor and when administered intranasally, has a potent anti- inflammatory action in the airway.”
“Following intravenous administration, the elimination phase half-life averaged 15.1 hours.”
“Fluticasone furoate is rapidly cleared (total plasma clearance of 58.7L/h) from systemic circulation principally by hepatic metabolism to an inactive 17beta-carboxylic metabolite, by the cytochrome P450 enzyme CYP3A4.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Fluticasone is a synthetic trifluorinated corticosteroid with high affinity for the glucocorticoid receptor, delivering potent topical anti-inflammatory activity when administered intranasally. It is TGA-approved for treatment of seasonal and perennial allergic rhinitis in adults and children aged 2 years and older. Following systemic absorption, fluticasone undergoes rapid hepatic metabolism via CYP3A4 to an inactive 17β-carboxylic acid metabolite; elimination half-life averages 10 hours intranasally and 15.1 hours following intravenous administration, with total plasma clearance of 58.7 L/h.
Epistaxis, nasopharyngitis, nasal ulceration, headache, and back pain are recognised adverse effects. Hypersensitivity reactions—including anaphylaxis, angioedema, rash, and urticaria—nasal septum perforation, and growth retardation constitute serious adverse events. Fluticasone is contraindicated in patients with hypersensitivity to any component of the preparation. Co-administration with strong CYP3A4 inhibitors may increase systemic corticosteroid exposure.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.